1 Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009.CA Cancer J Clin,2009,59:225-249. 2 Edgell T,Martin-Roussety G,Barker G,et al.Phase Ⅱbiomarker trial of a multimarker diagnostic for ovarian canaer.J Cancer Res Clin Oncol,2010,136:1079-1088. 3 李楠.MicroRNA在卵巢癌中的研究进展.现代妇产科进展,2013,22:765-766. 4 Resnick KE,Alder H,Hagan JP,et al.Richardson DL,Croce CM,Cohn DE.The detection of differentially expressed microRNAs form the serum of ovarian cancer patients using a novel real-time PCR platform.Gynecol Oncol,2009,112:55-59. 5 叶海燕,陈建国.人类微小RNA let-7a在卵巢上皮细胞癌中的表达及临床意义.中国实用妇科与产科杂志,2013,29:794-797. 6 Hu X,Macdonald DM,Huettner PC,et al.A mir-200 microRNA cluster as prognostic marker in advanced ovarian cancer.Gynecol Oncol,2009,114:457-464. 7 Taylor DD,Gercel-Taylor C.MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.Gynecol Oncol,2008,110:13-21. 8 柳兰英.卵巢上皮癌组织中HMGA1的表达及意义.现代肿瘤医学,2007,15:538-539. 9 许永华,李长贤,陈杰,等.高迁移率蛋白A1(HMGA1)在肝细胞癌中的表达及临床意义.南京医科大学学报(自然科学版),2010,3:304-310. 10 王宇熙,郑建华,张广美,等.高迁移率蛋白A1与人附睾分泌蛋白4、CA125联合检测上皮性卵巢癌的临床价值.中国实用妇科与产科杂志,2013,9:741-744. 11 Feng K,Zhou HJ,Hu YL.Effect of cinobufotalin on growth of xenograft of endometrial carcinoma cell line ishikawa in nude mouse and its impact on RRM2 expression.Zhongguo Zhong Xi Yi Jie He Za Zhi,2010,30:1183-1185. 12 Ferrandina G,Mey V,Nannizzi S,et al.Expression of nucleoside transporters,deoxycytidine kinase,ribonucleotide reductase regulatory subunits,and gemcitabine catabolic enzymes in primary ovarian cancer.Cancer Chemother Pharmacol,2010,65:679-686. 13 王菲,王黎明,张梦,等.上皮性卵巢癌患者外周血中RRM2 的表达及临床意义.现代妇产科进展,2013,22:288-291. 14 Moore RC,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Gynecol Oncol,2008,108:402-408. 15 Havrilesky LJ,Whitehead CM,Rubatt JM,et al.Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.Gynecol Oncol,2008,110:374-382. 16 Li J,Dowdy J,Tipton T,et al.HE4 as a biomarker for ovarian and endometrial cancer management.Expert RevMol Diagn,2009,9:555-566. 17 Galpano MT,Hampton GM,Frierson HF.Comprehensive analysis of HE4 expression in normal and malignant human tissue.Mod Pathol,2006,19:847-853. 18 Anastasi E,Marchei GG,Viggiani V,et al.HE4:a new potential early biomarker for the recurrence of ovarian cancer.Tumor Biol,2010,31:113-119. 19 Kong SY,Han MH,Yoo HJ,et al.Serum HE4 Level is an independent prognostic factor in epithelial ovarian cancer.Ann Surg Oncol,2012,19:1707-1712. 20 Anderson MR,Goff BA,Lowe KA,et al.Use of a Symptom Index,CA125 and HE4 to predict ovarian cancer.Gynecol Oncol,2010,116:378-383.
